Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better”

Group 1 - Moderna, Inc. is highlighted as a noteworthy stock in the S&P 500, with a significant increase of nearly 50% in January [1] - The company experienced a dramatic decline of 95% from its peak in 2021 to its lows in November 2022, but has since nearly doubled from those lows [1] - Moderna is expected to return to revenue growth in 2026 for the first time since 2021, following a positive investor day event [1] Group 2 - Moderna specializes in mRNA medicines and vaccines for illnesses such as flu and COVID-19, and is also developing treatments for cancer and rare diseases [1]